Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression data from human mesenchymal stromal cells from osteoarthritis donors treated with the chemokine CCL25

ABSTRACT: Osteoarthritis (OA) is a chronic, multifactorial disease of the joint, which involves synovial inflammation, bone remodeling, and cartilage destruction. It poses a serious burden of global disease, with an incidence rate that has increased by 9.3% between 1990 and 2017. In situ tissue engineering represents a strategy that takes advantage of physiological repair mechanisms and seeks to enhance them. A strong focus has been placed on mesenchymal stromal cells (MSCs) as a source for endogenous regeneration, as they have been shown to contribute to tissue recovery in OA and other pathologies like myocardial infarction and injured liver or pancreas tissue. CCL25, also known as TECK, is a chemokine that has been prevsiously shown to recruit MSCs. We used a microarry analysis to elucidate the broader effect of the chemokine CCL25 on mesenchymal stromal cells derived from patients with osteoarthritis.

ORGANISM(S): Homo sapiens

PROVIDER: GSE267906 | GEO | 2025/12/10

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Comparison of mesenchymal stromal cells derived from osteoarthritis and non-osteoarthritis patients

Project description:Osteoarthritis (OA) is a chronic, multifactorial disease of the joint, which involves synovial inflammation, bone remodeling, and cartilage destruction. It poses a serious burden of global disease, with an incidence rate that has increased by 9.3% between 1990 and 2017. In situ tissue engineering represents a strategy that takes advantage of physiological repair mechanisms and seeks to enhance them. A strong focus has been placed on mesenchymal stromal cells (MSCs) as a source for endogenous regeneration, as they have been shown to contribute to tissue recovery in OA. A potential senescent phenotype of OA MSCs could impose a major limitation on their regenerative potential. MSCs derived from the bone marrow of osteoarthritis and non-osteoarthritis patients were analyzed upon their expression of senescence markers using an affymetrix microarray to explore their suitability for an in situ tissue engineering approach.

2025-12-10 | GSE267908 | GEO

Expression data from human mesenchymal stromal cells from osteoarthritis donors treated with the chemokine CCL25

Project description:Expression data from human mesenchymal stromal cells from osteoarthritis donors treated with the chemokine CCL25

| PRJNA1113622 | ENA

MSCs OA SILAC Mass spectrometry imaging

Project description:In osteoarthritis (OA), impairment of cartilage regeneration can be related to a defective chondrogenic differentiation of mesenchymal stromal cells (MSCs). Therefore, understanding the proteomic- and metabolomic-associated molecular events during the chondrogenesis of MSCs could provide alternative targets for therapeutic intervention. Here, a SILAC-based proteomic analysis identified 43 proteins related with metabolic pathways whose abundance was significantly altered during the chondrogenesis of OA human bone marrow MSCs (hBMSCs). Then, the level and distribution of metabolites was analyzed in these cells and healthy controls by matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI), leading to the recognition of characteristic metabolomic profiles at the early stages of differentiation. Finally, integrative pathway analysis showed that UDP-glucuronic acid synthesis and amino sugar metabolism were downregulated in OA hBMSCs during chondrogenesis compared to healthy cells. Alterations in these metabolic pathways may disturb the production of hyaluronic acid (HA) and other relevant cartilage extracellular matrix (ECM) components. This work provides a novel integrative insight into the molecular alterations of osteoarthritic MSCs and potential therapeutic targets for OA drug development through the enhancement of chondrogenesis.

2020-01-27 | PXD012879 | Pride

Global Extracellular Vesicle Proteome Changes Across Time Upon Intraarticular Treatment of Mesenchymal Stromal Cells in an In Vivo model of Equine Osteoarthritis

Project description:Equine Osteoarthritis (OA) is a heterogeneous, degenerative disease of the musculoskeletal system with multifactorial causation, characterised by joint metabolic imbalance. Mesenchymal stromal cell therapy (MSC) is a form of regenerative medicine that utilises MSC properties to repair damaged tissues. MSCs have been described as acting via the paracrine signalling of secreted factors. Despite its wide use in veterinary clinical practices, the exact mechanism of action of MSCs has not been fully characterised. Here, we have characterised synovial fluid extracellular vesicles (EVs) from control, osteoarthritic and MSC treated animals in order to gain insights into this mechanism. An in vivo, carpal osteochondral fragment model of equine OA was used for this study. Six horses underwent surgical intervention. All horses enrolled in the study were female trotter horses between the ages of 4 and 7. The contralateral limb of each horse served as a sham control. 69 synovial fluid samples were collected via aseptic arthrocentesis at day 0, 18, 21, 28, 35, and 70. Allogenic mesenchymal stromal cell therapy from male donors was injected into the OA afflicted joint after day 18. Synovial fluid (200µl) was Hyalaronidase treated (1µg/ml) and EVs were isolated using differential ultracentrifugation. EVs were characterised in collaboration with Nanoview Biosciences, whereby the Exoview human tetraspanin assay was used. EV concentration, surface marker identification, fluorescent microscopy and tetraspanin colocalization analysis was performed using pooled samples reflecting experimental groups - control, OA and OA including MSCs - across time.

2023-03-11 | PXD035303 | Pride

Adipose-derived mesenchymal stem cell extracellular vesicles downregulate inflammation in osteoarthritis chondrocytes and cartilage explants

Project description:Osteoarthritis (OA) is a joint condition associated with articular cartilage loss, low-grade synovitis and alterations in subchondral bone and periarticular tissues. In OA, the interest for mesenchymal stem cell (MSC)-EV therapeutic applications has increased. We have assessed the immunomodulary properties of adipose-derived MSCs (AD-MSCs) microvesicles (MV) and exosomes (EX) in interleukin (IL)-1β stimulated OA chondrocytes and cartilage explants and characterized them by mass spectrometry in order to uncover novel mediators in (AD-MSC)-EV immunomodulation.

2022-02-23 | PXD009077 | Pride

Metabolic reprogramming: Targeting inhibition of osteoarthritis-induced pyruvate dehydrogenase kinase expression preserves mitochondrial respiration

Project description:Fibroblast-like synoviocytes (FLS) maintain the structural and dynamic integrity of joints. Additionally, FLS have been identified as key drivers of joint destruction in osteoarthritis (OA). Pathogenic THY1+ FLS are classified as invasively proliferative cells. However, little is known about the metabolic changes of FLS in the pathogenesis of OA. Here, we demonstrate functional, proteomic, and metabolic characteristics of inflammation-exposed FLS compared with unexposed fibroblast-like mesenchymal stromal cells (MSCs) from patients with OA. Analysis of FLS and MSC proteomes revealed 592 differentially expressed proteins. Although both cell types were indistinguishable according to classical markers, pathway analysis revealed that pyruvate dehydrogenase kinase (PDK) 3 is highly expressed only in proliferative FLS. Inhibition of PDKs by dichloroacetate significantly shifted glycolysis to oxidative phosphorylation while reducing proliferation without causing cell death. Therefore, reprogramming FLS metabolism from glycolysis to mitochondrial respiration by inhibiting PDK isoforms might be a new approach to treat transformed FLS in OA

2022-03-31 | PXD027215 | Pride

Implication of bone marrow adipose tissue in bone homeostasis during osteoarthritis

Project description:Objective: To explore the role of bone marrow adipocytes (BMAds) in osteoarthritis (OA). Methods: Male and female C57BL/6 mice (n=4/group) underwent meniscectomy (MNX) or SHAM surgery. OA was determined using OARSI score and the number of perilipin+ adipocytes was quantified. Mesenchymal Stromal Cells (MSCs) from MNX and SHAM mice were differentiated into osteoblasts and adipocytes. Human adipocytes and MSCs (n=8) were enzymatically isolated from epiphyseal and metaphyseal marrow, and from subcutaneous adipose tissue (SCAT) of hip OA patients. Human OA MSCs were differentiated into osteoblasts and adipocytes (OA-Diff-hAdipo). Gene expression patterns of epiphyseal and metaphyseal BMAds, SCAT adipocytes and OA-Diff-hAdipo were evaluated by RNAseq (n=4). The effect conditioned media from OA epiphyseal bone (n=5) on the alkaline phosphatase (ALP) activity and mineralization kinetics was assessed in vitro. Results: Increase in BMAd density was positively correlated with cartilage degradation in MNX mice. OA modified the differentiation capacity of MSCs, accelerating adipocyte differentiation and failing to produce osteoblasts in both human and mice. Human epiphyseal, metaphyseal and SCAT adipocytes from the same OA patients each displayed a specific transcriptome, suggesting different functions. Enrichment analysis defined metaphyseal OA-BMAds as cells implicated in hematopoietic stem cell differentiation. On the other hand, epiphyseal OA-BMAds were considered as osteogenic cells showing an up-regulation of genes related to bone mineralization and remodeling. Specifically, OA epiphysis-secreted molecules decreased ALP activity and altered in vitro the mineralization process. Conclusion: All these results support the emergence of BMAds as new cell partners in OA, opening new venues for therapeutic approaches.

2025-03-13 | GSE291355 | GEO

Equine muscle-derived mesenchymal stem cells protect cartilage explants in osteoarthritis model: secretome characterization

Project description:Background: Osteoarthritis is a highly prevalent joint degenerative disease for which therapeutic treatments are limited or invasive. Cell therapy based on mesenchymal stem/stromal cells (MSCs) is therefore seen as a promising approach for this disease, in both human and horses. Objective: As the regenerative potential of MSCs is mainly conferred by paracrine function, the goal of this study is to characterize the secretome of muscle-derived MSCs (mdMSCs) in an in vitro model of OA to evaluate the clinical interest of mdMSCs as cell therapy for joint diseases like osteoarthritis. Methods: An equine osteoarthritis model composed of cartilage explants exposed to pro-inflammatory cytokines was first developed. Then, the effects of mdMSC coculture on cartilage explant were studied by measuring the glycosaminoglycan release and the NO2- production. To identify the underlying molecular actors, SILAC-based secretome analyses were conducted, in the presence of serum. The relative abundance of highly sequenced proteins was finally confirmed by western blot. Results: Co-culture with muscle-derived MSCs decreases the cytokine-induced glycosaminoglycan release by cartilage explants, suggesting a protecting effect of mdMSCs. Among the 52 equine proteins sequenced in the co-culture medium, the abundance of decorin and matrix metalloproteinase 3 was modified, as confirmed by western blot analyses. Conclusions: These results suggest that muscle-derived MSCs could reduce the catabolic effect of TNF and IL-1 on cartilage explant by decreasing the secretion and activity of Matrix Metalloproteinase 3 and increasing the decorin secretion

2022-11-08 | PXD031924 | Pride

A Chondrogenic Molecule that Repairs Cartilage by Transcriptional Regulation of CBF-beta

Project description:Osteoarthritis (OA) is a degenerative joint disease that involves destruction of articular cartilage and eventually leads to disability. Mesenchymal stem cells (MSCs) reside in healthy and diseased cartilage, and through their chondrogenic potential may provide a strategy for cartilage repair. To this end, we performed an image-based, high throughput screen and identified the small molecule, kartogenin, that promotes selective MSC differentiation into chondrocytes (EC50=100nM), shows chondroprotective effects in vitro, and is efficacious in two OA animal models. Kartogenin binds filamin A and induces chondrogenesis by regulating the CBFbeta-RUNX1 transcriptional program. This work provides new insights into the control of chondrogenesis that may ultimately lead to an effective stem-cell based therapy for osteoarthritis. one compound, three doses, two time points, a vehicle control

2012-05-01 | E-GEOD-35546 | biostudies-arrayexpress

Comparison between articular chondrocytes and mesenchymal stromal cells for the production of articular chondrocyte implants

Project description:Focal lesions of articular cartilage give rise to pain and reduced joint function and may, if left untreated, lead to osteoarthritis. Implantation of in vitro generated, scaffold-free autologous cartilage discs may represent the best treatment option. Here we compare articular chondrocytes (ACs) and bone marrow-derived mesenchymal stromal cells (MSCs) for their ability to make scaffold-free cartilage discs.

2023-02-07 | PXD029434 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data